Researchers at Dankook University and Korea University Research & Business Foundation Sejong Campus have identified thiophene derivatives acting as lysine-specific demethylase 4C (KDM4C; GASC-1; JMJD2C) inhibitors reported to be useful for the treatment of Alzheimer’s disease.
Scientists at Technical Institute of Physics and Chemistry, Chinese Academy of Sciences have disclosed hypocrellin derivatives acting as photosensitizers for photodynamic therapy reported to be useful for the treatment of cancer, bacterial infections and fungal infections.
Hefei Institutes of Physical Sciences has synthesized new pyrazoleamide compounds acting as receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of cancer, Crohn’s, Graves, Parkinson’s disease, ischemia, sepsis, multiple sclerosis and HIV infection.
Interline Therapeutics Inc. has identified new compounds receptor-interacting serine/threonine-protein kinase 2 (RIPK2; RIP-2) inhibitors reported to be useful for the treatment of inflammatory bowel disease (IBD).
Park City Bio LLC has prepared and tested new serotonin receptor agonists reported to be useful for the treatment of pain, inflammation, psychiatric and neurological disorders.
Gilead Sciences Inc. has reported new compounds acting as phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of cancer.
Solu Therapeutics Inc. has identified heterobifunctional cotinine-containing compounds acting as sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers or sodium channel protein type 9 subunit α (SCN9A; Nav1.7) blockers. They are reported to be useful for the treatment of pain, cough and pruritus.